Literature DB >> 18039917

Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening.

Yingjia Zhang1, Peter Weady, Rohit Duggal, Weidong Hao.   

Abstract

A major obstacle in hepatitis C virus (HCV) research has been the lack of a permissive cell culture system that produces infectious viral particles. Significant breakthroughs have been achieved lately in establishing such culture systems. Yet to date, there are no reports of the applications of any of these systems in HCV drug screening. Here, we report the generation of two monocistronic, chimeric genotype 1 full-length HCV genome molecules. These molecules, C33J-Y835C-UBI and C33J-Y835C-FMDV2A, both contain the structural protein region from genotype 1 (subtype 1b, Con1) and the remaining region from the genotype 2a (JFH1) clone. Both contain the humanized Renilla luciferase reporter gene which is separated from the rest of the HCV open reading frame by two different cleavage sites. The viral RNAs replicated efficiently in transfected cells. Viral particles produced were infectious in naïve Huh7.5 cells, and the infectivity could be blocked by monoclonal antibody against a putative HCV entry cofactor, CD81. A pilot high-throughput screen of 900 unknown compounds was executed by both the genotype 2a subgenomic replicon system and the infectious system. Thirty-one compounds were identified as hits by both systems, whereas 78 compounds were identified as hits only for the infectious system, suggesting that the infectious system is capable of identifying inhibitors targeting the viral structural proteins and steps involving them in the viral life cycle. The infectious HCV system developed here provides a useful and versatile tool which should greatly facilitate the identification of HCV inhibitors currently not identified by the subgenomic replicon system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18039917      PMCID: PMC2224717          DOI: 10.1128/AAC.01133-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Ubiquitination.

Authors:  D Finley; V Chau
Journal:  Annu Rev Cell Biol       Date:  1991

Review 2.  The ubiquitin pathway for protein degradation.

Authors:  A Hershko
Journal:  Trends Biochem Sci       Date:  1991-07       Impact factor: 13.807

3.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

4.  Enhanced in vivo selection of bone marrow cells by retroviral-mediated coexpression of mutant O6-methylguanine-DNA-methyltransferase and HOXB4.

Authors:  Michael D Milsom; Lorna B Woolford; Geoffrey P Margison; R Keith Humphries; Leslie J Fairbairn
Journal:  Mol Ther       Date:  2004-11       Impact factor: 11.454

5.  CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection.

Authors:  Daisuke Akazawa; Tomoko Date; Kenichi Morikawa; Asako Murayama; Michiko Miyamoto; Minako Kaga; Heidi Barth; Thomas F Baumert; Jean Dubuisson; Takaji Wakita
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

6.  Binding of hepatitis C virus to CD81.

Authors:  P Pileri; Y Uematsu; S Campagnoli; G Galli; F Falugi; R Petracca; A J Weiner; M Houghton; D Rosa; G Grandi; S Abrignani
Journal:  Science       Date:  1998-10-30       Impact factor: 47.728

7.  Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence.

Authors:  M D Ryan; A M King; G P Thomas
Journal:  J Gen Virol       Date:  1991-11       Impact factor: 3.891

8.  Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

Authors:  V Lohmann; F Körner; J Koch; U Herian; L Theilmann; R Bartenschlager
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

9.  Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations.

Authors:  N Krieger; V Lohmann; R Bartenschlager
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 10.  Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C.

Authors:  Thomas Hügle; Andreas Cerny
Journal:  Rev Med Virol       Date:  2003 Nov-Dec       Impact factor: 6.989

View more
  9 in total

1.  Knockdown of USP18 increases α 2a interferon signaling and induction of interferon-stimulating genes but does not increase antiviral activity in Huh7 cells.

Authors:  E J Murray; Frances Burden; Nigel Horscroft; Caroline Smith-Burchnell; Mike Westby
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 2.  Hepatitis C virus experimental model systems and antiviral drug research.

Authors:  Susan L Uprichard
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

3.  Screening compounds against HCV based on MAVS/IFN-β pathway in a replicon model.

Authors:  Qiu-Xia Fu; Li-Cui Wang; Shuai-Zheng Jia; Bo Gao; Yong Zhou; Juan Du; Ying-Li Wang; Xiao-Hui Wang; Jian-Chun Peng; Lin-Sheng Zhan
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

4.  Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening.

Authors:  Xuemei Yu; Bruno Sainz; Susan L Uprichard
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

5.  Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection.

Authors:  Kao-Lu Pan; Jin-Ching Lee; Hsing-Wen Sung; Teng-Yuang Chang; John T-A Hsu
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

6.  Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor.

Authors:  Hui-Mei Lin; Jing-Chyi Wang; Han-Shu Hu; Pei-Shan Wu; Chi-Chen Yang; Chung-Pu Wu; Szu-Yuan Pu; Tsu-An Hsu; Weir-Torn Jiaang; Yu-Sheng Chao; Jyh-Haur Chern; Teng-Kuang Yeh; Andrew Yueh
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

7.  Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.

Authors:  Hui-Mei Lin; Jing-Chyi Wang; Han-Shu Hu; Pei-Shan Wu; Wen-Hung Wang; Su-Ying Wu; Chi-Chen Yang; Teng-Kuang Yeh; Tsu-An Hsu; Weir-Torn Jiaang; Yu-Sheng Chao; Jyh-Haur Chern; Andrew Yueh
Journal:  Antimicrob Agents Chemother       Date:  2012-11-19       Impact factor: 5.191

8.  Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.

Authors:  Glen A Coburn; Danielle N Fisch; Sameer M Moorji; Jean-Marc de Muys; Jose D Murga; Dorothy Paul; Kathleen P Provoncha; Yakov Rotshteyn; Amy Q Han; Dapeng Qian; Paul J Maddon; William C Olson
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

9.  Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized mice.

Authors:  Jizheng Chen; Yang Zhao; Chao Zhang; Hairong Chen; Jin Feng; Xiumei Chi; Yu Pan; Jun Du; Min Guo; Huang Cao; Honghe Chen; Zilong Wang; Rongjuan Pei; Qian Wang; Lei Pan; Junqi Niu; Xinwen Chen; Hong Tang
Journal:  Cell Res       Date:  2014-08-26       Impact factor: 25.617

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.